Alkermes Inc

Type: Company
Name: Alkermes Inc
Nationality: United States
Web Address: http://www.alkermes.com/
Fact Sheet: Fact Sheet for Alkermes Inc
First reported 2 hours ago - Updated 2 hours ago - 1 reports

Who's Next Pharma on the Tax Inversion Bullseye?

According to Bloomberg, that list would include Perrigo Co., in Ireland and Actelion Ltd, in Switzerland. Both would offer US acquirers the chance to redomicile to friendlier tax environs and cut their corporate rates by up to 1/3. It's all the rage you ... [Published The Big Red Biotech Blog - 2 hours ago]
First reported 8 hours ago - Updated 8 hours ago - 1 reports

Alkermes

plc – A Global Biopharmaceutical CompanyAlkermes applies its scientific expertise and technological know-how to develop innovative medicines designed to help patients with serious, chronic conditions better manage their disease.Our CompanyLatest NewsYou ... [Published Bioresearch Online - 8 hours ago]
First reported 8 hours ago - Updated 8 hours ago - 1 reports

Alkermes Starts Phase I Study Of Potential MS Treatment

By Lori ClapperDublin drug manufacturer Alkermes has initiated a phase I clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule intended for the treatment of multiple sclerosis (MS). The launch of this trial could hopefully lead to some ... [Published Bioresearch Online - 8 hours ago]
First reported Jul 21 2014 - Updated 17 hours ago - 3 reports

Alkermes Kicks Off Its Phase 1 Clinical Study of ALKS 8700

Alkermes has initiated the phase 1 clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis (MS). According to a release from the company, the randomized, double-blind study will evaluate ... [Published Individual.com - 17 hours ago]
First reported Jul 19 2014 - Updated Jul 19 2014 - 1 reports

Patent Office Reports Notices of Allowance for Alkermes' Pipeline Candidates

Alkermes said that the United States Patent and Trademark Office(USPTO) issued Notices of Allowance for four of Alkermes' pipelinecandidates for the treatment of central nervous system (CNS)disorders: aripiprazole lauroxil, ALKS 5461, ALKS 3831 and A ... [Published HighBeam Research - Jul 19 2014]
First reported Jul 18 2014 - Updated Jul 19 2014 - 2 reports

Patent Office Reports Notices of Allowance for Alkermes' Pipeline Candidates

Alkermes said that the United States Patent and Trademark Office (USPTO) issued Notices of Allowance for four of Alkermes' pipeline candidates for the treatment of central nervous system (CNS) disorders: aripiprazole lauroxil, ALKS 5461, ALKS 3831 and ... [Published 4 Traders - Jul 19 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

East Coast Biotech Roundup: Acceleron, Seres, Sage, & More

7/18/14 Follow @benthefidlerThe megamerger resurfaced this week, as Dublin’s Shire, a rumored acquisition target on and off for years that has 1,500 employees in Lexington, MA, agreed to be bought by North Chicago, IL-based AbbVie in a $55 billion tax ... [Published Xconomy - Jul 18 2014]
First reported Jul 17 2014 - Updated Jul 18 2014 - 8 reports

Alkermes begins Phase I trial of ALKS 8700 to treat multiple sclerosis

Ireland-based biopharmaceutical firm Alkermes has started a Phase I clinical trial of ALKS 8700, a novel monomethyl fumarate (MMF) molecule being developed for the treatment of multiple sclerosis (MS). ... [Published PBR - News - Jul 18 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

21st Century Cures Initiatives Examines Care from A Patient’s Perspective

On July 11th, 2014, the House Energy and Commerce Health Subcommittee convened a hearing entitled "21st Century Cures: Incorporating the Patient Perspective". The hearing was part of the ongoing 21st Century Cures Initiative, a bipartisan effort to accelerate ... [Published HIMSS - Jul 18 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 2 reports

Alkermes (ALKS) Showing Bearish Technicals

After closing Tuesday at $46.80, Alkermes Inc (ALKS) presents an attractive opportunity to get a 11.89% return in just 129 days, which is an annualized return of 33.64% (for comparison purposes only). To enter this trade, sell one Nov. '14 $48.00 call ... [Published MarketIntelligenceCenter.com - Jul 16 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Alkermes is Among the Companies in the Biotechnology Industry With the Highest Forward P/E Ratio (ALKS, VRTX, RGEN, SVA, SPPI)

(Comtex SmarTrend(R)) Below are the three companies in the Biotechnology industry with the highest forward price to earnings (P/E) ratios. Forward P/E uses estimated earnings to compare relative value among companies in the same industry. Generally, ... [Published Individual.com - Jul 15 2014]
First reported Jul 09 2014 - Updated Jul 10 2014 - 7 reports

Alkermes gets notices of allowance for US patents for four CNS pipeline candidates

Alkermes has announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for four of Alkermes’ pipeline candidates for the treatment of central nervous system (CNS) disorders: aripiprazole lauroxil, ALKS 5461, ... [Published PBR - News - Jul 10 2014]

Quotes

...Elliot Ehrich, CMO of Alkermes, said. "ALKS 8700 leverages Alkermes' expertise in prodrug chemistry and oral controlled-release formulations to offer potential differentiated tolerability and dosing for patients with MS."
Aripiprazole lauroxil: The USPTO issued a Notice of Allowance for U S Patent Application 13/607,066, entitled "Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders." Alkermes expects this patent to issue within the next few months and expire no earlier than September 2030
...Ajani said there are many reasons why doing business in Italy is difficult but focused on one particular problem. "If you are not a friend of a friend, everything is difficult" he said. Having increased sales by 400% from 2006 to 2013, Cosmo is now looking to expand sales in the U S through its deal with Salix and bring its...

More Content

All (247) | News (112) | Reports (0) | Blogs (124) | Audio/Video (0) | Fact Sheets (1) | Press Releases (10)
sort by: Date | Relevance
Who's Next Pharma on the Tax Inversion Bullseye? [Published The Big Red Biotech Blog - 2 hours ago]
'Volunteers' Fighting Marijuana Legalization in... [Published High Times - 7 hours ago]
Jay-Z and Scarface: pharma staff’s anonymous Wi... [Published In-Pharmatechnologist - 7 hours ago]
Alkermes Starts Phase I Study Of Potential MS T... [Published Bioresearch Online - 8 hours ago]
Alkermes [Published Bioresearch Online - 8 hours ago]
Alkermes (ALKS) Trading Near $46.69 Resistance ... [Published MarketIntelligenceCenter.com - 11 hours ago]
Despite The Sell-Off, Zohydro Is A Falling Knif... [Published Seeking Alpha - 12 hours ago]
Alkermes Kicks Off Its Phase 1 Clinical Study o... [Published Individual.com - 17 hours ago]
Alkermes' Pipeline Development Impresses, Key U... [Published Zacks.com - Jul 21 2014]
Alkermes (ALKS) Showing Bearish Technicals With... [Published MarketIntelligenceCenter.com - Jul 21 2014]
Patent Office Reports Notices of Allowance for ... [Published HighBeam Research - Jul 19 2014]
Can Anything Stop Drug Companies From Fleeing T... [Published Forbes.com - Jul 19 2014]
Patent Office Reports Notices of Allowance for ... [Published 4 Traders - Jul 19 2014]
Alkermes begins Phase 1 clinical study of ALKS ... [Published Individual.com - Jul 18 2014]
East Coast Biotech Roundup: Acceleron, Seres, S... [Published Xconomy - Jul 18 2014]
Potential Alkermes (ALKS) Trade Has 8.56% Downs... [Published MarketIntelligenceCenter.com - Jul 18 2014]
Alkermes begins Phase I trial of ALKS 8700 to t... [Published PBR - News - Jul 18 2014]
21st Century Cures Initiatives Examines Care fr... [Published HIMSS - Jul 18 2014]
U.K. gov names ex-biotech VC as life sci chief,... [Published FierceBiotech - Jul 18 2014]
Alkermes takes its Tecfidera beater into clinic... [Published FierceBiotech - Jul 17 2014]
Phase 1 started for Alkermes MS drug candidate [Published Seeking Alpha - Jul 17 2014]
What we can learn from Neil Woodford’s new port... [Published Money Week - Jul 17 2014]
Alkermes (ALKS) Showing Bearish Technicals With... [Published MarketIntelligenceCenter.com - Jul 17 2014]
Alkermes Begins Phase 1 Study Of ALKS 8700 For ... [Published RTTNews.com - Jul 17 2014]
Alkermes Announces Initiation of Phase 1 Clinic... [Published SearchBug - Jul 17 2014]
Alkermes Announces Initiation of Phase 1 Clinic... [Published EON Business - Jul 17 2014]
Alkermes Announces Initiation of Phase 1 Clinic... [Published Business Wire Professional Services News - Jul 17 2014]
Alkermes Announces Initiation of Phase 1 Clinic... [Published Business Wire Health News - Jul 17 2014]
Hypocrisy of Big Pharma - Anti-Cannabis Lobbying [Published Daily Kos - Jul 17 2014]
Alkermes (ALKS) Showing Bearish Technicals [Published MarketIntelligenceCenter.com - Jul 16 2014]
1 2 3 4 5 6 7 8 9
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Who's Next Pharma on the Tax Inversion Bullseye? [Published The Big Red Biotech Blog - 2 hours ago]
According to Bloomberg, that list would include Perrigo Co., in Ireland and Actelion Ltd, in Switzerland. Both would offer US acquirers the chance to redomicile to friendlier tax environs and cut their corporate rates by up to 1/3. It's all the rage you ...
Alkermes (ALKS) Trading Near $46.69 Resistance ... [Published MarketIntelligenceCenter.com - 11 hours ago]
After closing Monday at $45.91, Alkermes Inc (ALKS) presents an attractive opportunity to get a 11.08% return in just 123 days, which is an annualized return of 32.89% (for comparison purposes only). To enter this trade, sell one Nov. '14 $47.00 call ...
Alkermes (ALKS) Showing Bearish Technicals With... [Published MarketIntelligenceCenter.com - Jul 21 2014]
After closing Friday at $46.15, Alkermes Inc (ALKS) presents an attractive opportunity to get a 10.98% return in just 124 days, which is an annualized return of 32.32% (for comparison purposes only). To enter this trade, sell one Nov. '14 $47.00 call ...
Potential Alkermes (ALKS) Trade Has 8.56% Downs... [Published MarketIntelligenceCenter.com - Jul 18 2014]
After Thursday’s trading in Alkermes Inc (ALKS) the option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center uncovered a trade that offers a 10.86% return, or 31.23% annualized (for comparison purposes only), ...
Alkermes begins Phase I trial of ALKS 8700 to t... [Published PBR - News - Jul 18 2014]
Ireland-based biopharmaceutical firm Alkermes has started a Phase I clinical trial of ALKS 8700, a novel monomethyl fumarate (MMF) molecule being developed for the treatment of multiple sclerosis (MS). ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Clinical Trial Data, NDA Submissions, and Board... [Published Financial Services - Jun 25 2014]
Biotech Equities Under Review -- Research on Ac... [Published Financial Services - May 09 2014]
Priority Reviews, Preliminary Earnings Releases... [Published Financial Services - Apr 11 2014]
Certifications, Authorizations, Stock Updates, ... [Published Financial Services - Apr 10 2014]
Health Care Stocks Technical Coverage -- Resear... [Published Financial Services - Apr 09 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.